Cadrenal Therapeutics, Inc. (CVKD) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing tecarfarin, a novel oral vitamin K antagonist (VKA) designed as a safer alternative to warfarin for patients with specific cardiovascular conditions, including end-stage kidney disease (ESKD) with atrial fibrillation and patients with left ventricular assist devices (LVADs). The company holds Orphan Drug and Fast-Track designations for these indications. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(3.67) million | $(7.51) million | N/A |
| Operating Expenses | $(3.73) million | $(7.66) million | N/A |
| Cash and Equivalents | N/A | N/A | $5.57 million |
| Working Capital | N/A | N/A | $4.29 million |
| Accumulated Deficit | N/A | N/A | $(33.24) million |
| Cash Used in Operations (YTD) | N/A | $(7.67) million | N/A |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the six months ended June 30, 2025, increased to $7.51 million from $4.06 million in the same period in 2024. This represents a 85% increase in losses.
- Operating Expenses: Total operating expenses rose to $7.66 million (YTD 2025) from $4.22 million (YTD 2024).
- General & Administrative (G&A): Increased by $2.57 million (110%) due to higher public company costs, stock-based compensation, and personnel expenses.
- Research & Development (R&D): Increased by $0.86 million (46%) driven by chemistry, manufacturing, and controls (CMC) costs and severance for a former Chief Medical Officer.
- Liquidity: Cash and cash equivalents decreased from $10.02 million at December 31, 2024, to $5.57 million at June 30, 2025, primarily due to operating cash burn.
- Capital Raising: The company raised approximately $3.20 million in net proceeds through its At-The-Market (ATM) facility during the first six months of 2025.
Outlook, Risks, and Management Commentary
- Clinical Progress: On August 5, 2025, the company announced plans to initiate a Phase 3 clinical trial for tecarfarin in patients with ESKD transitioning to dialysis. Enrollment is expected to begin later in 2025.
- Liquidity Risk: Management states that cash on hand (approximately $5.0 million as of August 6, 2025) is sufficient to fund operations for at least the next twelve months. However, additional funding is required to conduct further late-stage clinical trials.
- Financing Strategy: The company intends to raise additional funds through partnering, equity sales, or debt financing. There is no assurance that such funding will be available on acceptable terms.
- Going Concern: The financial statements are prepared assuming the company will continue as a going concern, though significant losses and negative cash flows persist.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.57 million cash balance against the projected costs of the upcoming Phase 3 trial and general operating expenses.
- ATM Facility Usage: Monitor the frequency and pricing of shares sold via the ATM facility, noting the recent weighted average price of $12.97 per share in July 2025.
- Clinical Milestones: Confirm the start date and enrollment progress of the ESKD Phase 3 trial announced in August 2025.
- Expense Management: Review the trajectory of G&A expenses, which have more than doubled year-over-year, to assess burn rate sustainability.
- Dilution Risk: Assess the impact of outstanding warrants (615,940 shares) and options (433,001 shares) on future share count and potential dilution.